Quality of Artemisinin-Containing Antimalarials in Tanzania's Private Sector--Results from a Nationally Representative Outlet Survey. by Act Consortium Drug Quality Project Team And The Impact Study Te
ACT Consortium Drug Quality Project Team and the IMPACT2
Study T (2015) Quality of Artemisinin-Containing Antimalarials in
Tanzania’s Private Sector–Results from a Nationally Representative
Outlet Survey. The American journal of tropical medicine and hy-
giene, 92 (6 Suppl). pp. 75-86. ISSN 0002-9637 DOI: 10.4269/ajtmh.14-
0544
Downloaded from: http://researchonline.lshtm.ac.uk/2299109/
DOI: 10.4269/ajtmh.14-0544
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
SUPPLEMENTAL INFORMATION
DETAILS OF LABORATORY ANALYSIS
High-performance liquid chromatography (HPLC) analy-
sis at the London School of Hygiene & Tropical Medicine
(LSHTM; United Kingdom) was conducted using a Dionex
Ultimate 3000 system (Thermofisher, Hemel Hempstead,
United Kingdom) and separation achieved using a GENESIS
AQ 4-mm column (150 + 4.6 mm; Grace Materials Technolo-
gies, Cranforth, United Kingdom). The mobile phase was a
gradient of ammonium formate (10 mM, pH 2.7) and acetoni-
trile (v/v; 60:40 to 85:15 over 7.0 minutes). A photo-diode array
unit (ultraviolet [UV]-PDA; DAD 3000) was set at 204 nm for
the artemisinin derivatives (artesunate, artemether, dihydroar-
temisinin [DHA]), 360 nm for piperaquine, amodiaquine and
lumefantrine and 259 nm for MF. In all cases, the flow rate
used was 1.0 mL/min. Calibration curves of each compound
were generated by Thermofisher Scientific Dionex Chromeleon
7.2 chromatography data system (CDS) software using known
amounts of the corresponding chemical standards. Reference
standards of artemisinin, artesunate, artemether, DHA,
amodiaquine dichlorodihydrate, and pyrimethamine were pur-
chased from Sigma Aldrich, United Kingdom. Lumefantrine
was purchased from World Health Organization (WHO),
Switzerland. Mefloquine and sulfadoxine (SP) were a gift from
Roche, Basel, Switzerland, and sulfamethoxypyrazine was a gift
from Dafra PHARMA, Belgium. Results were expressed as a
percentage of the stated amounts of API on the package.
Samples analyzed at LSHTM were sent without the original
packaging to two collaborative laboratories at the Georgia
Institute of Technology (GT), Atlanta, GA, for MS screening
of all samples and the U.S. Centers for Disease Control and
Prevention (CDC) Laboratories Atlanta, GA for HPLC con-
firmatory analysis on a subsample of 14% samples.
HPLC analysis methodology at CDC. In brief, all tablets
were pulverized, dissolved in the appropriate solvent and fil-
tered using a 0.22 mm nylon membrane. A portion of the extract
was injected into the high-performance liquid chromatographic
(HPLC) system. Component separation was achieved using a
150 + 4.6 mm octadecyl silica column and a mobile phase
consisting of various proportions of acetonitrile and 0.05 M
perchlorate buffer adjusted to a pH of 2.5 with UV detection.
The Bland–Altman plot in Supplemental Figure 1 illus-
trates the between-laboratory differences of drug samples
analyzed by CDC and LSHTM. The mean difference between
laboratory results (bias) is 0.15 %API (95% confidence inter-
val [CI]: −0.75 to 1.0) with no significant difference from zero.
The 95% CI for the limits of agreement is −19.6 to 19.9 %API
for all active ingredients analyzed by both laboratories. Con-
sidering that the exact same tablets could not be analyzed by
both laboratories, the different HPLC methods used and con-
sidering intertablet variability, this was considered a reason-
able level of agreement.
MS analysis at GT. MS analyses of drug samples were
performed using a direct analysis in real time (DART) ion
source coupled to a time-of-flight mass spectrometer (TOF
MS). A commercial DART-100 ion source (IonSense, Saugus,
MA) was used in-line with a Bruker micrOTOF-Q I mass
spectrometer (Bremen, Germany). Detailed description of
the DART-100 ion source is available elsewhere.49,50
The DART ion source ceramic nozzle was positioned 1 cm
away and in-line with the MS inlet. The DART working gas
(high purity He, 99.995% Airgas, Atlanta, GA) was supplied
to the ion source at a flow rate of 1 L/min and was heated to
250°C. The DART ion source was operated at a needle elec-
trode voltage of −4,000 V, a discharge grid voltage of +200 V,
and exit grid voltage of +200 V. These conditions were found
to provide maximum sensitivity and good chemical detectabil-
ity for the various species investigated. To prevent gas over-
load on the MS vacuum system from the gas flow exiting the
ion source, a Vapur interface (IonSense) was used. The MS
voltage settings were optimized for maximum ion transmis-
sion of 50–1,200 Da with end plate offset −500 V, capillary
−2,000 V, dry gas (nitrogen) 1.2 L/min, capillary 200°C, spec-
tra acquired at 1 Hz in the 50–1,200 m/z range in positive ion
detection mode.
The instrument was mass calibrated using a 10 mM metha-
nol solution of polyethylene glycol (PEG) 400, PEG 600, and
PEG 1000 calibration standards. During calibration, continu-
ous supply of the calibration standard solution for ionization
by DART was maintained by delivering the standard solution
through a 10-mm i.d. silica capillary in front of the ion source
at a flow rate of 3 mL/min using a KD Scientific syringe pump
(New Hope, PA). The mass spectrometer provided a mass
resolution of ~12,000 at m/z 393.2095 and ~9,000 at m/z
151.0964, and a typical mass accuracy of 2–5 ppm was obtained
for acetaminophen as test compound.
All experiments were performed in positive ion detection
mode and all samples were analyzed under identical instru-
mental conditions. For MS analysis of pharmaceuticals in tab-
let form, the coating was scratched by a razor blade, a few
tablet particles were obtained by scratching the inside and
outside surfaces of the tablet, the particles were placed on a
Kimwipe (Kimberly-Clark Corporation, Dallas, TX), and
deposited on the tip of a glass capillary by rubbing it against
the Kimwipe. Any liquid injectables were deposited on the
capillary by dipping the tip of the glass capillary in the liquid
sample vial. The capillary tip with the deposited sample was
then introduced in front of the plasma plume exiting the
DART source for sample ionization and subsequent detection
by mass spectrometry.
The Bruker Daltonics DataAnalysis version 4.0 software
package was used for processing of all acquired data. Pres-
ence and identity of active pharmaceutical ingredient(s)
(API or APIs) in samples were established by matching m/
z values measured by the mass spectrometer with the calcu-
lated exact m/z values (within a maximum uncertainty of
0.005 Da) of the API, together with the isotopic abun-
dances, and adduct, or fragment ions listed in an in-house
built database.
The MS analysis confirmed that all samples contained the
stated artemisinin and partner active ingredient, and no other
active ingredients were identified.
Supplemental TABLE 2
Adjusted ORs of being poor quality based on both artemisinin and
partner components for selected ACTs by risk factors where P < 0.2
in bivariate analysis, controlling for whether drugs were expired at
time of analysis
N
Number of
poor quality Adjusted OR* P value
Generic type 0.2
Artemether 599 16 1
Artemisinin 298 4 2.1 (0.3–14.2)
Artesunate 539 46 3.6 (1.0–13.4)
Dihydroartemisinin 294 23 1.9 (1.1–3.4)
WHO prequalified 0.002
No 1,442 85 1
Yes 308 4 0.1 (0.01–0.34)
Dose form 0.1
Tablet 1,385 55 1
Suspension 192 11 1.3 (0.3–5.6)
Injectable 107 3 1.3 (0.4–4.8)
Granule 46 20 8.3 (1.3–54.8)
Stated region of manufacture 0.1
Asia 850 32 1
Africa 435 15 0.9 (0.4–2.2)
Europe 412 41 3.6 (1.0–13.1)
United States 17 1 0.2 (0.02–1.7)
Price per AETD 0.06
< 25th percentile 133 9 1
³ 25th percentile 1,599 80 2.9 (0.9–8.4)
ACTs = artemisinin-based combination therapies; AETD = adult equivalent treatment
dose; OR = odds ratio; WHO =World Health Organization.
Poor quality defined as less than 85% or greater than 115% of stated active pharmaceuti-
cal ingredient (API).
*After controlling for whether expired at time of analysis.
Supplemental TABLE 1
Adjusted ORs of being poor quality based on artemisinin component
only by risk factors where P < 0.2 in bivariate analysis, controlling
for whether drugs were expired at time of analysis
N
Number of
poor quality Adjusted OR* P value
Generic type 0.01
Artemether 499 17 1
Artemisinin 173 14 5.2 (1.2–22.9)
Artesunate 310 65 7.0 (1.9–25.7)
Dihydroartemisinin 294 39 7.3 (2.3–23.5)
WHO prequalified < 0.001
No 1,015 130 1
Yes 256 5 0.04 (0.01–0.2)
Dose form 0.1
Tablet 1,040 99 1
Suspension 192 12 0.6 (0.2–2.3)
Injectable 0 0 −
Granule 44 24 3.4 (0.6–19.1)
Stated region of manufacture 0.05
Asia 657 56 1
Africa 186 12 0.5 (0.1–1.7)
Europe 404 66 0.9 (0.3–2.5)
United States 17 1 0.03 (1.2–6.2)
Price per AETD 0.06
< 25th percentile 70 8 1
³ 25th percentile 1,206 127 3.3 (0.7–11.4)
ACTs = artemisinin-based combination therapies; AETD = adult equivalent treatment
dose; OR = odds ratio; WHO =World Health Organization.
Poor quality defined as less than 85% or greater than 115% of stated active pharmaceuti-
cal ingredient (API).
*After controlling for whether expired at time of analysis.
Supplemental Figure 1. Bland–Altman plot of inter laboratory
comparison of percent active pharmaceutical ingredients (%APIs)
determined from U.S. Centers for Disease Control and Prevention
(CDC) and London School of Hygiene and Tropical Medicine
(LSHTM) laboratories. Data include the analysis of artemether,
artesunate, dihydroartemisinin, lumefantrine, mefloquine, and
piperaquine (N = 488).
